



Cytokinetics to Participate in Upcoming Investor Conferences

February 3, 2016 9:00 PM EST

SOUTH SAN FRANCISCO, Calif., Feb. 03, 2016 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq:CYTK) announced today that Robert I. Blum, President and Chief Executive Officer, is scheduled to present at the 18th Annual BIO CEO & Investor Conference on Monday, February 8, 2016 at 1:30 PM EST at the Waldorf Astoria in New York, NY. Members of Cytokinetics' senior management team will also participate in the SunTrust Robinson Humphrey 2016 Orphan Drug Day on Tuesday, February 23, 2016 at the JW Marriott Essex House in New York, NY.

Interested parties may access the live webcast of the BIO CEO presentation by visiting the Investors & Media section of the Cytokinetics website at www.cytokinetics.com. The webcast replay of the presentation will be archived on the Presentations page within the Investors & Media section of Cytokinetics' website until May 8, 2016.

About Cytokinetics

Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. As a leader in muscle biology and the mechanics of muscle performance, the company is developing small molecule drug candidates specifically engineered to increase muscle function and contractility. Cytokinetics' lead drug candidate is *tirasemtiv*, a fast skeletal muscle activator, for the potential treatment of ALS. *Tirasemtiv* has been granted orphan drug designation and fast track status by the U.S. Food and Drug Administration and orphan medicinal product designation by the European Medicines Agency for the potential treatment of ALS. Cytokinetics retains the right to develop and commercialize *tirasemtiv*. Cytokinetics is collaborating with Amgen Inc. to develop *omecamtiv mecarbil*, a novel cardiac muscle activator, for the potential treatment of heart failure. Cytokinetics is collaborating with Astellas Pharma Inc. to develop CK-2127107, a fast skeletal muscle activator, for the potential treatment of spinal muscular atrophy. Amgen holds an exclusive license worldwide to develop and commercialize *omecamtiv mecarbil* and Astellas holds an exclusive license worldwide to develop and commercialize CK-2127107. Both licenses are subject to Cytokinetics' specified development and commercialization participation rights. For additional information about Cytokinetics, visit www.cytokinetics.com.

Contact: []
Cytokinetics []
Diane Weiser
Vice President, Corporate Communications, Investor Relations
(650) 624-3060



Cytokinetics, Inc